Published in Antimicrob Agents Chemother on October 01, 1998
Differences in patterns of infection and inflammation for corticosteroid treatment and chemotherapy in experimental invasive pulmonary aspergillosis. Infect Immun (2005) 1.99
In vitro activities of the new antifungal triazole SCH 56592 against common and emerging yeast pathogens. Antimicrob Agents Chemother (2000) 1.68
Efficacy of FK463, a new lipopeptide antifungal agent, in mouse models of pulmonary aspergillosis. Antimicrob Agents Chemother (2000) 1.48
Antifungal triazoles and polymorphonuclear leukocytes synergize to cause increased hyphal damage to Scedosporium prolificans and Scedosporium apiospermum. Antimicrob Agents Chemother (2002) 1.01
Interactions of posaconazole and flucytosine against Cryptococcus neoformans. Antimicrob Agents Chemother (2001) 0.88
Antifungal activities of posaconazole and granulocyte-macrophage colony-stimulating factor ex vivo and in mice with disseminated infection due to Scedosporium prolificans. Antimicrob Agents Chemother (2004) 0.83
Experimental therapy with azoles against Candida guilliermondii. Antimicrob Agents Chemother (2014) 0.76
Anidulafungin in treatment of experimental invasive infection by Candida parapsilosis: in vitro activity, (1-->3)-beta-D-glucan and mannan serum levels, histopathological findings, and in vivo efficacy. Antimicrob Agents Chemother (2011) 0.76
Inflammatory cells' role in acetic acid-induced colitis. Adv Biomed Res (2014) 0.75
Effect of granulocyte colony-stimulating factor combination therapy on efficacy of posaconazole (SCH56592) in an inhalation model of murine pulmonary aspergillosis. Antimicrob Agents Chemother (2004) 0.75
Nebulised amphotericin B-polymethacrylic acid nanoparticle prophylaxis prevents invasive aspergillosis. Nanomedicine (2015) 0.75
Treatment options in Invasive Aspergillosis. Curr Treat Options Infect Dis (2014) 0.75
Combined therapies in a murine model of blastoschizomycosis. Antimicrob Agents Chemother (2007) 0.75
Rodent Models of Invasive Aspergillosis due to Aspergillus fumigatus: Still a Long Path toward Standardization. Front Microbiol (2017) 0.75
Antifungal and surgical treatment of invasive aspergillosis: review of 2,121 published cases. Rev Infect Dis (1991) 6.43
Quality control guidelines for National Committee for Clinical Laboratory Standards recommended broth macrodilution testing of amphotericin B, fluconazole, and flucytosine. J Clin Microbiol (1995) 6.02
Selective protection against conidia by mononuclear and against mycelia by polymorphonuclear phagocytes in resistance to Aspergillus. Observations on these two lines of defense in vivo and in vitro with human and mouse phagocytes. J Clin Invest (1982) 4.71
Pulmonary aspergillosis in the acquired immunodeficiency syndrome. N Engl J Med (1991) 3.69
Damage to hyphal forms of fungi by human leukocytes in vitro. A possible host defense mechanism in aspergillosis and mucormycosis. Am J Pathol (1978) 2.66
Chronic necrotizing pulmonary aspergillosis: a discrete clinical entity. Medicine (Baltimore) (1982) 2.62
The effect of cortisone and antibiotic agents on experimental pulmonary aspergillosis. Am J Pathol (1959) 2.00
Prevention of corticosteroid-induced suppression of human polymorphonuclear leukocyte-induced damage of Aspergillus fumigatus hyphae by granulocyte colony-stimulating factor and gamma interferon. Infect Immun (1993) 1.95
Invasive aspergillosis in patients with AIDS. Clin Infect Dis (1994) 1.80
"Semi-invasive" pulmonary aspergillosis: a new look at the spectrum of aspergillus infections of the lung. Radiology (1981) 1.73
Granulocyte colony-stimulating factor enhances the phagocytic and bactericidal activity of normal and defective human neutrophils. J Infect Dis (1991) 1.70
Killing of Aspergillus spores depends on the anatomical source of the macrophage. Infect Immun (1983) 1.68
Mechanisms of resistance of Aspergillus fumigatus Conidia to killing by neutrophils in vitro. J Infect Dis (1985) 1.58
Pathogenesis of pulmonary aspergillosis. Granulocytopenia versus cyclosporine and methylprednisolone-induced immunosuppression. Am J Respir Crit Care Med (1995) 1.55
Infections with Aspergillus species. Clin Infect Dis (1993) 1.26
Progress in the diagnosis and management of aspergillosis in bone marrow transplantation: 13 years' experience. Clin Infect Dis (1993) 1.19
Invasive aspergillosis in patients with AIDS. Clin Infect Dis (1992) 1.16
Acquired immunity in experimental murine aspergillosis is mediated by macrophages. Infect Immun (1993) 1.07
Granulocyte colony-stimulating factor administered in vivo augments neutrophil-mediated activity against opportunistic fungal pathogens. J Infect Dis (1997) 1.02
Pulmonary cavitation and massive hemoptysis in invasive pulmonary aspergillosis. Influence of bone marrow recovery in patients with acute leukemia. Am Rev Respir Dis (1985) 1.00
Impairment of neutrophil antifungal activity against hyphae of Aspergillus fumigatus in children infected with human immunodeficiency virus. J Infect Dis (1993) 0.98
Invasive aspergillosis with massive fatal hemoptysis in patients with neoplastic disease. Chest (1980) 0.98
Fatal disseminated aspergillosis in an asthmatic patient treated with corticosteroids. Chest (1983) 0.95
Inhibition of monocyte-mediated damage to fungal hyphae by steroid hormones. J Infect Dis (1983) 0.94
Disseminated aspergillosis. Aspergillus endophthalmitis, optic nerve infarction, and carotid artery thrombosis. Arch Pathol (1975) 0.92
Protective effect of human granulocyte colony-stimulating factor (hG-CSF) on Cryptococcus and Aspergillus infections in normal and immunosuppressed mice. Mycoses (1992) 0.92
Invasive pulmonary aspergillosis in an apparently nonimmunocompromised host. Am J Med (1980) 0.89
Antifungal combination therapy with granulocyte colony-stimulating factor and fluconazole in experimental disseminated candidiasis. Eur J Clin Microbiol Infect Dis (1995) 0.85
Disseminated aspergillosis in an apparently healthy patient. Am J Med (1990) 0.84
Granulocyte-colony stimulating factor facilitates the restoration of resistance to opportunistic fungi in leukopenic mice. J Med Vet Mycol (1992) 0.81
Treatment of invasive pulmonary aspergillosis in severely neutropenic children with malignant disorders using liposomal amphotericin B (AmBisome), granulocyte colony-stimulating factor, and surgery: report of five cases. Pediatr Hematol Oncol (1996) 0.81
Immunomodulators and fungal infections: use of antifungal drugs in combination with G-CSF. Adv Exp Med Biol (1992) 0.81
Epidemiology of invasive aspergillosis in European cancer centres. EORTC Invasive Fungal Infections Cooperative Group. Eur J Clin Microbiol Infect Dis (1993) 0.81
Localized invasive pulmonary aspergillosis in patients with neutropenia. Effectiveness of surgical resection. Cancer (1993) 0.79
Treatment of aspergillosis in leukemia. Ann Intern Med (1979) 0.78
Use of cytokines in the treatment of acute myelocytic leukemia: a critical review. J Clin Oncol (1996) 0.78
Resection of mycotic lung sequestra after invasive aspergillosis. Ann Thorac Surg (1993) 0.77
Pulmonary aspergillosis in an unselected hospital population. Chest (1971) 0.77
Nonfilamentous C. albicans mutants are avirulent. Cell (1997) 13.83
In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts. Antimicrob Agents Chemother (2006) 3.25
In vitro and in vivo activities of SCH 56592 (posaconazole), a new triazole antifungal agent, against Aspergillus and Candida. Antimicrob Agents Chemother (2000) 2.33
Comparison of a new triazole antifungal agent, Schering 56592, with itraconazole and amphotericin B for treatment of histoplasmosis in immunocompetent mice. Antimicrob Agents Chemother (1999) 2.06
A comparative study of the in vitro susceptibilities of clinical and laboratory-selected resistant isolates of Aspergillus spp. to amphotericin B, itraconazole, voriconazole and posaconazole (SCH 56592). J Antimicrob Chemother (2000) 1.98
Treatment of murine disseminated candidiasis with L-743,872. Antimicrob Agents Chemother (1997) 1.87
Activities of the triazole derivative SCH 56592 (posaconazole) against drug-resistant strains of the protozoan parasite Trypanosoma (Schizotrypanum) cruzi in immunocompetent and immunosuppressed murine hosts. Antimicrob Agents Chemother (2000) 1.87
Treatment of murine Candida krusei or Candida glabrata infection with L-743,872. Antimicrob Agents Chemother (1997) 1.83
Comparison of pathogenesis and host immune responses to Candida glabrata and Candida albicans in systemically infected immunocompetent mice. Infect Immun (2001) 1.75
Antiproliferative effects and mechanism of action of SCH 56592 against Trypanosoma (Schizotrypanum) cruzi: in vitro and in vivo studies. Antimicrob Agents Chemother (1998) 1.65
Pharmacokinetics of SCH 56592, a new azole broad-spectrum antifungal agent, in mice, rats, rabbits, dogs, and cynomolgus monkeys. Antimicrob Agents Chemother (2000) 1.64
SCH56592 treatment of murine invasive aspergillosis. J Antimicrob Chemother (1998) 1.55
Detection of Paracoccidioides brasiliensis in tissue samples by a nested PCR assay. J Clin Microbiol (2000) 1.44
Comparative pharmacokinetics of Sch 28191 and amphotericin B in mice, rats, dogs, and cynomolgus monkeys. Antimicrob Agents Chemother (1984) 1.31
Pharmacokinetics and tissue penetration of Sch 39304 in granulocytopenic and nongranulocytopenic rabbits. Antimicrob Agents Chemother (1989) 1.30
Antibiotic G418, a new micrommomospora-produced aminglycoside with activity apainst protozoa and helminths: antiparasitic activity. Antimicrob Agents Chemother (1975) 1.29
Variation in fluconazole efficacy for Candida albicans strains sequentially isolated from oral cavities of patients with AIDS in an experimental murine candidiasis model. Antimicrob Agents Chemother (1996) 1.28
Fluconazole versus Candida albicans: a complex relationship. Antimicrob Agents Chemother (1998) 1.27
Diagnosis and monitoring of murine histoplasmosis by a nested PCR assay. J Clin Microbiol (2001) 1.27
Stroke in infective endocarditis. Stroke (1990) 1.26
Efficacy of SCH56592 in a rabbit model of invasive aspergillosis. Antimicrob Agents Chemother (2000) 1.25
Combination therapy with fluconazole and flucytosine in the murine model of cryptococcal meningitis. Antimicrob Agents Chemother (1997) 1.23
Activities of sordarins in murine histoplasmosis. Antimicrob Agents Chemother (1999) 1.21
Evernimicin (SCH27899) inhibits a novel ribosome target site: analysis of 23S ribosomal DNA mutants. Antimicrob Agents Chemother (2000) 1.19
Cytokine networking in lungs of immunocompetent mice in response to inhaled Aspergillus fumigatus. Infect Immun (2001) 1.17
EmtA, a rRNA methyltransferase conferring high-level evernimicin resistance. Mol Microbiol (2001) 1.17
Treatment of histoplasmosis with MK-991 (L-743,872). Antimicrob Agents Chemother (1998) 1.16
SCH 56592, amphotericin B, or itraconazole therapy of experimental murine cerebral phaeohyphomycosis due to Ramichloridium obovoideum ("Ramichloridium mackenziei"). Antimicrob Agents Chemother (2000) 1.13
Fluconazole treatment of Candida albicans infection in mice: does in vitro susceptibility predict in vivo response? Antimicrob Agents Chemother (1995) 1.12
Comparison of fluconazole, amphotericin B and flucytosine in treatment of a murine model of disseminated infection with Candida glabrata in immunocompromised mice. J Antimicrob Chemother (1995) 1.10
Treatment of murine fusariosis with SCH 56592. Antimicrob Agents Chemother (1999) 1.07
Antifungal activity of amphotericin B cochleates against Candida albicans infection in a mouse model. Antimicrob Agents Chemother (2000) 1.07
Correlation between antifungal susceptibilities of Coccidioides immitis in vitro and antifungal treatment with caspofungin in a mouse model. Antimicrob Agents Chemother (2001) 1.02
Comparison of SCH 39304, fluconazole, and ketoconazole for treatment of systemic infections in mice. Antimicrob Agents Chemother (1992) 1.00
Fluconazole, D0870, and flucytosine treatment of disseminated Candida tropicalis infections in mice. Antimicrob Agents Chemother (1995) 0.99
Kijanimicin (Sch 25663), a novel antibiotic produced by Actinomadura kijaniata SCC 1256. Fermentation, isolation, characterization and biological properties. J Antibiot (Tokyo) (1981) 0.98
Treatment of disseminated Torulopsis glabrata infection with DO870 and amphotericin B. Antimicrob Agents Chemother (1994) 0.98
Granulocyte colony stimulating factor therapy of experimental cryptococcal meningitis. J Med Vet Mycol (1997) 0.96
Efficacy of the triazole SCH 56592 against Leishmania amazonensis and Leishmania donovani in experimental murine cutaneous and visceral leishmaniases. Antimicrob Agents Chemother (1999) 0.95
Immunomodulatory role of endogenous interleukin-18 in gamma interferon-mediated resolution of replicative Legionella pneumophila lung infection. Infect Immun (2000) 0.95
Efficacy of nikkomycin Z in the treatment of murine histoplasmosis. Antimicrob Agents Chemother (1998) 0.95
Efficacies of KY62 against Leishmania amazonensis and Leishmania donovani in experimental murine cutaneous leishmaniasis and visceral leishmaniasis. Antimicrob Agents Chemother (1998) 0.94
Sch 37137, a novel antifungal compound produced by a Micromonospora sp. Taxonomy, fermentation, isolation, structure and biological properties. J Antibiot (Tokyo) (1988) 0.92
Evaluation of SCH51048 in an experimental model of pulmonary aspergillosis. Antimicrob Agents Chemother (1995) 0.92
Liposomal amphotericin B therapy of murine histoplasmosis. Antimicrob Agents Chemother (1995) 0.91
Interspecies pharmacokinetic scaling of Sch 34343. J Antimicrob Chemother (1985) 0.91
Evaluation of the in-vitro activity of Sch 29482. J Antimicrob Chemother (1982) 0.91
Comparison of a new triazole, posaconazole, with itraconazole and amphotericin B for treatment of histoplasmosis following pulmonary challenge in immunocompromised mice. Antimicrob Agents Chemother (2000) 0.90
Therapeutic and prophylactic efficacy of aminocandin (IP960) against disseminated candidiasis in mice. Clin Microbiol Infect (2008) 0.90
Pharmacokinetics of Sch 34343 in rats and dogs. J Antimicrob Chemother (1985) 0.89
Interactions of posaconazole and flucytosine against Cryptococcus neoformans. Antimicrob Agents Chemother (2001) 0.88
N-aminoacyl derivatives of polyene macrolide antibiotics and their esters. J Antibiot (Tokyo) (1982) 0.88
An alternative animal model for comparison of treatments for cryptococcal meningitis. Antimicrob Agents Chemother (1999) 0.87
Evaluation of the in-vitro antibacterial activity of Sch 34343. J Antimicrob Chemother (1985) 0.87
The hazimicins, a new class of antibiotics. Taxonomy, fermentation, isolation, characterization and biological properties. J Antibiot (Tokyo) (1983) 0.86
Antifungal combination therapy with granulocyte colony-stimulating factor and fluconazole in experimental disseminated candidiasis. Eur J Clin Microbiol Infect Dis (1995) 0.85
Efficacy of SCH27899 in an animal model of Legionnaires' disease using immunocompromised A/J mice. Antimicrob Agents Chemother (2000) 0.85
Structure-activity relationships of synthetic antibiotic analogues of anisomycin. J Med Chem (1983) 0.85
Comparison of SCH 39304 and its isomers, RR 42427 and SS 42426, for treatment of murine cryptococcal and coccidioidal meningitis. Antimicrob Agents Chemother (1992) 0.83
Sch 29482, a new penem antibiotic: evaluation of in-vitro activity and effect of test conditions. J Antimicrob Chemother (1982) 0.83
Antifungal activities of posaconazole and granulocyte-macrophage colony-stimulating factor ex vivo and in mice with disseminated infection due to Scedosporium prolificans. Antimicrob Agents Chemother (2004) 0.83
Efficiency of lower threshold criteria for the diagnosis of gestational diabetes. Obstet Gynecol (1995) 0.83
Comparative in vitro and in vivo antifungal activity of tolnaftate and various undecylenates. J Pharm Sci (1980) 0.81
KY-62, a polyene analog of amphotericin B, for treatment of murine candidiasis. Antimicrob Agents Chemother (1998) 0.81
ZD0870 treatment of murine candidiasis caused by fluconazole resistant isolates of Candida albicans. J Antimicrob Chemother (1996) 0.81
Treatment of experimental cryptococcosis with SCH 39304 and fluconazole. Antimicrob Agents Chemother (1991) 0.81
Comparison of anidulafungin's and fluconazole's in vivo activity in neutropenic and non-neutropenic models of invasive candidiasis. Clin Microbiol Infect (2011) 0.80
Susceptibility of pneumococci to evernimicin: effect of CO2 and different methodologies. Clin Microbiol Infect (2001) 0.80
Oxanthromicin, a novel antibiotic from Actinomadura. J Antibiot (Tokyo) (1984) 0.80
Synthesis and antifungal properties of 14-aminomethyl-substituted lanosterol derivatives. Ann N Y Acad Sci (1988) 0.80
Comparative in vitro and in vivo evaluation of N-D-ornithyl amphotericin B methyl ester, amphotericin B methyl ester, and amphotericin B. Antimicrob Agents Chemother (1987) 0.80
Discrepancy between in vitro and in vivo antifungal activity of albendazole. J Med Vet Mycol (1997) 0.79
Cocaine impairs follicular phase pulsatile gonadotropin secretion in rhesus monkeys. J Soc Gynecol Investig (1999) 0.79
Treatment of Mycobacterium haemophilum infection in a murine model with clarithromycin, rifabutin, and ciprofloxacin. Antimicrob Agents Chemother (1995) 0.79
Macrolactams: two novel homologous series of compounds produced by Actinomadura sp. SCC 1778. J Antibiot (Tokyo) (1992) 0.78
Pharmacokinetics of an everninomicin (SCH 27899) in mice, rats, rabbits, and cynomolgus monkeys following intravenous administration. Antimicrob Agents Chemother (2000) 0.78
Sch 31828, a novel antibiotic from a Microbispora sp.: taxonomy, fermentation, isolation and biological properties. J Antibiot (Tokyo) (1988) 0.78
Semisynthetic aminoglycoside antibacterials. 6. Synthesis of sisomicin, Antibiotic G-52, and novel 6'-substituted analogues of sisomicin from aminoglycoside 66-40C. J Med Chem (1978) 0.78
Sch 54445: a new polycyclic xanthone with highly potent antifungal activity produced by Actinoplanes sp. J Nat Prod (1997) 0.78
Effects of follicular-phase cocaine administration on menstrual and ovarian cyclicity in rhesus monkeys. Am J Obstet Gynecol (1998) 0.77
Low-dose follicular-phase cocaine administration disrupts menstrual and ovarian cyclicity in rhesus monkeys. J Soc Gynecol Investig (1999) 0.77
Microbiological and pharmacokinetic studies of acyl demycinosyltylosin and related tylosin derivatives. J Antibiot (Tokyo) (1990) 0.77
Bleomycin therapy of experimental disseminated candidiasis in mice. Antimicrob Agents Chemother (1996) 0.77
A novel phenazine antifungal antibiotic, 1,6-dihydroxy-2-chlorophenazine. Fermentation, isolation, structure and biological properties. J Antibiot (Tokyo) (1984) 0.77